This review demonstrates advancements in aptamer-based degradation, indicating new therapeutic possibilities for undruggable targets.
Conventional targeted protein degradation (TPD) is often ineffective against many disease-related proteins. This review summarizes recent advances in aptamer-based TPD for the degradation of “undruggable” targets, expanding therapeutic possibilities.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: